On the fly News and insights, exclusive to thefly.com

VIR

Vir Biotechnology

$34.95 /

+13.49 (+62.86%)

05:03
02/27/20
02/27
05:03
02/27/20
05:03

Vir Biotechnology downgraded to Underperform from Neutral at Baird

Baird analyst Madhu Kumar downgraded Vir Biotechnology to Underperform from Neutral with an unchanged price target of $17. The stock closed Wednesday up 61% to $34.98. The shares have more than doubled in the past five business days despite an absence of significant data for the company's pipeline, Kumar tells investors in a research note. As such, Vir is now "deeply over-valued," says the analyst. Kumar is interested in the first half of 2020 Phase 1/2 results for the company's hepatitis B virus candidate VIR-2218, but believes the current the valuation "has gone well beyond even clinical success from these results." Further, Vir is nowhere close to an effective therapeutic for COVID-19, adds the analyst.

  • 02

    Mar

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.